DiaSorin S.p.A. is an Italy-based biotechnology company specializing in the development, manufacturing and distribution of in vitro diagnostic systems. The company’s core activities center on immunodiagnostics and molecular diagnostics, offering a comprehensive portfolio of reagents, instruments and automated platforms to detect a wide range of diseases. Its solutions support clinical laboratories, hospitals, blood banks and pharmaceutical companies in identifying infectious agents, monitoring chronic conditions and managing patient care.
The company’s product lineup includes the LIAISON® family of chemiluminescence immunoassay (CLIA) systems, which cover key therapeutic areas such as infectious diseases, endocrinology, bone and joint health, fertility, oncology and cardiovascular screening. In molecular diagnostics, DiaSorin provides molecular assays for respiratory pathogens, blood screening, genetic tests and transplant monitoring. These offerings are complemented by digital connectivity tools that streamline laboratory workflows and improve data management.
Founded in 1968 in Saluggia, Italy, DiaSorin has grown through organic expansion and targeted acquisitions to establish a presence in more than 30 countries worldwide. The company operates multiple manufacturing and R&D sites across Europe, North America, Latin America and the Asia-Pacific region. This global footprint enables DiaSorin to tailor its diagnostics solutions to local regulatory requirements and healthcare needs.
Innovation remains at the heart of DiaSorin’s strategy, with significant investments in research and development each year. The company collaborates with universities, hospitals and industry partners to advance diagnostic technology and address emerging health challenges. Under the leadership of CEO Carlo Rosa and a seasoned management team, DiaSorin continues to pursue growth opportunities while maintaining a focus on quality, reliability and scientific excellence.
AI Generated. May Contain Errors.
